To the Editors,

We thank Drs. Frommelt, Kory, and Long for their interest in the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) trial and their recommendation to carefully consider time to treatment in our analysis plan. As they have pointed out, our inclusion criteria require study drug administration within 28 h of the onset of first qualifying organ dysfunction \[[@CR1]\]. While it is unknown what differential effect time to hydrocortisone, ascorbic acid, and thiamine (commonly referred to as HAT therapy) may have on patients with sepsis, we agree early treatment with other therapeutics has improved outcomes in sepsis \[[@CR2]\]. However, in planning the VICTAS trial, we chose to allow a moderately wide enrollment window reasoning that HAT therapy, if effective, would be of interest to providers managing patients along a wide spectrum of illness severity.

Since completing enrollment in the VICTAS trial in late 2019, discussions of trials exploring the benefits of therapeutic regimens like the one we tested have broadened. While much focus at the time VICTAS was designed was on the question of the efficacy of HAT, negative trials have stimulated a discussion as to when HAT therapy could be effective \[[@CR3], [@CR4]\].

In response, we have calculated the time between first qualifying organ dysfunction and first dose of study intervention in the VICTAS trial. This will be reported along with other participant characteristics and will be included in our adjusted analyses following the same approach as described for other covariates. Specifically, we will use restricted cubic splines to address potential non-linearities, and we will assess for a differential treatment effect. This will be done by testing the interaction between time to treatment and treatment assignment. If the interaction achieves a *P* value ≤ 0.2, we will consider the possibility of subgroup analyses with grouping informed by the relationship between time to treatment and outcomes. Since the approach was specified a priori, this helps to mitigate the post hoc addition of this covariate. We expect that including this important variable will strengthen our findings given the suggestion that time to treatment may modify the response to treatment.

HAT

:   Hydrocortisone, ascorbic acid, and thiamine

VICTAS

:   Vitamin C, Thiamine and Steroids in Sepsis
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All authors provided input to the decisions reflected in this response and approved the letter. All authors read and approved the final manuscript.

Funding for VICTAS was provided by the Marcus Foundation via contract to Emory University, the study sponsor. Neither the sponsor nor the funding agency has had any role in the design, execution, or planned analyses for this study. They have had no input on the writing of this letter and will have no input to future updates of the statistical analysis plan. Point-of-care glucometers were loaned to some study sites by Nova Biomedical, which has had no role in the design, execution, or planned analyses of the study, nor the writing of this letter.

A de-identified dataset from participants in the VICTAS trial will be made publicly available approximately 1 year after publication of the primary manuscript.

The VICTAS study was approved by a central IRB (Johns Hopkins University IRB protocol number: IRB00164053). Each site's local IRB approved the Informed Consent Document for local use and formally relied on this central approval before enrollment proceeded at that site. This study is registered with [ClinicalTrials.gov](http://clinicaltrials.gov) as NCT03509350.
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